SUBSCRIBE
SUBSCRIBE
News   Drug Development

Novartis AG Stops Tasigna Trial in Patients with GIST

April 11, 2011 | 
1 min read
ZURICH, April 11 (Reuters) - Novartis AG (NOVN.VX) has stopped a late-stage trial for Tasigna in intestinal tumors after a committee said the cancer drug was unlikely to show it was more effective than Glivec, the current standard of care.
Clinical research Phase 3
Novartis
MORE ON THIS TOPIC
Business people and concepts vector art exit
Business
Takeda’s long-term R&D head announces exit after major pipeline reorganization
September 10, 2026
 · 
2 min read
 · 
Gabrielle Masson
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
FDA
Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug
September 10, 2026
 · 
3 min read
 · 
Heather McKenzie
Vector cartoon illustration of a business team standing at a crossroad with multiple arrows, discussing and choosing the right path toward success and future opportunities.
Drug pricing
Drugmakers cherry pick launch regions as MFN creates ‘policy environment like an earthquake’
September 10, 2026
 · 
4 min read
 · 
Annalee Armstrong
Composite collage picture image of man slide down arrow recession statistics data weird freak bizarre unusual fantasy billboard comics.
Bladder cancer
Tyra shares slip as bladder cancer responses fall short of investor expectations
September 10, 2026
 · 
2 min read
 · 
Tristan Manalac